MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-06-2025
InMode Ltd. Total Assets 2011-2026 | INMD
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets InMode Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 786 M | 863 M | 644 M | 479 M | 296 M | 218 M | 81.1 M | 39.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 863 M | 39.4 M | 426 M |
Quarterly Total Assets InMode Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 479 M | - | - | - | 296 M | - | - | - | 218 M | - | - | - | 81.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 479 M | 81.1 M | 268 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B |  USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
776 M | $ 21.04 | 0.86 % | $ 3.01 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 9.4 | 1.08 % | $ 675 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.5 | 1.74 % | $ 121 M | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 95.35 | -0.69 % | $ 140 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 302.99 | -0.5 % | $ 8.55 B | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 29.12 | 1.01 % | $ 246 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 47.11 | -0.84 % | $ 7.02 K | USA |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 125.29 | -0.39 % | $ 218 B | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.29 | 2.49 % | $ 123 M |  France |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 97.28 | -0.5 % | $ 1.23 B | USA |
 |
LivaNova PLC
LIVN
|
2.51 B | $ 61.53 | -1.2 % | $ 3.34 B |  Britain |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
|
LENSAR
LNSR
|
66.3 M | $ 11.63 | - | $ 134 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Zynex
ZYXI
|
122 M | - | - | $ 21.1 M | USA |
 |
Orthofix Medical
OFIX
|
893 M | $ 15.16 | -1.11 % | $ 578 M |  Curacao |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Profound Medical Corp.
PROF
|
43.9 M | $ 7.87 | 7.37 % | $ 180 M | Canada |
 |
Align Technology
ALGN
|
6.21 B | $ 156.15 | -1.26 % | $ 11.7 B | USA |
 |
Accuray Incorporated
ARAY
|
470 M | $ 0.82 | 2.64 % | $ 84.3 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 13.68 | 0.81 % | $ 370 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.56 | -0.22 % | $ 122 M | USA |
 |
AxoGen
AXGN
|
204 M | $ 32.73 | - | $ 1.45 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.14 | -0.87 % | $ 18.4 M | USA |
 |
Sintx Technologies
SINT
|
15.4 M | $ 3.86 | 2.66 % | $ 14.4 M | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 40.6 | -1.31 % | $ 1.25 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
473 M | $ 17.76 | -1.11 % | $ 410 M | USA |